Regulatory Flexibility Clarified: Why Execution, Not Easing, Defines the Next Phase of CGT Manufacturing

Key Takeaways

• FDA regulatory flexibility for cell and gene therapies is a clarification, not deregulation, emphasizing phase-appropriate CMC controls without reducing expectations for safety, purity, or potency.

• Scientific justification and risk-based process understanding now define compliance, making comparability, validation, and release strategies central to development success across the product life cycle.

• CDMOs play a critical strategic role in translating regulatory flexibility into operational control, acting as continuity anchors for tech transfer, multi-site manufacturing, and inspection readiness.

• Automation, closed systems, PAT, and RTRT are enablers of flexible manufacturing — but only when grounded in data and disciplined execution, not treated as shortcuts or regulatory workarounds.

• Misinterpreting flexibility as reduced oversight risks undermining confidence in the entire CGT sector, making manufacturing strategy and execution quality decisive competitive differentiators for sponsors and partners.

The U.S. Food and Drug Administration’s (FDA) recent announcement on flexibility in chemistry, manufacturing, and controls (CMC) for cell and gene therapies (CGTs) is presented as a regulatory shift.¹ In practice, however, it represents something more modest and more consequential: a public articulation of how the agency has already been operating behind the scenes. Rather than relaxing standards, the FDA is making implicit decision-making frameworks explicit — bringing long-standing, case-by-case practices into the open.

Regulatory experts caution that this distinction matters. As Patrick Ginty, Ph.D., Director and Principal Consultant at VectusBio Consulting and a veteran of CGT regulatory interactions with both the FDA and European agencies, puts it, “Nothing has changed in the rules themselves, and this is not new guidance. What’s changed is the transparency around how those rules are applied in practice.” From this perspective, the announcement reflects accumulated regulatory experience across dozens of approvals and late-stage programs, not a departure from scientific rigor.

The greater risk lies in how the message is interpreted by less experienced stakeholders. Matthew Hewitt, Ph.D., Vice President and Chief Technical Officer of the Manufacturing Business Division at Charles River Laboratories warns that codifying flexibility could unintentionally widen the gap between academic development and commercial manufacturing. “Once something is written down, people can read it with different interpretations,” he observed. “A little knowledge like this has the potential to increase complexity depending on perspective.”

In that sense, the announcement is less about easing expectations than about clarifying them. Flexibility is framed as conditional — rooted in process understanding, risk assessment, and scientific justification — rather than as an open-ended concession. For sponsors and manufacturing partners, the practical implications are not philosophical but operational: how this clarity reshapes manufacturing strategy, technology choices, and partner selection across the development life cycle.

If the agency’s flexibility with regard to CMC requirements is not new, the critical question becomes: what is actually changing in practice — and what is not?

The FDA’s announcement draws an important line between flexibility in execution and permanence in standards. While investigational CGT products are not expected to meet the full requirements of 21 CFR Part 211 during early clinical development, this does not represent a relaxation of expectations for product quality. Instead, the agency reiterates a phase-appropriate approach to release criteria and manufacturing controls, recognizing that early-stage programs operate with limited data and small patient populations. As Ginty notes, this principle is not new: “Phase-appropriate expectations for GMP and setting specifications are already referenced in existing FDA guidance for CGT products. What’s different now is that they’ve said it out loud.”

A similar reframing applies to comparability. The FDA explicitly cautions against submitting “overly stringent and onerous” comparability packages and emphasizes that minor manufacturing changes may be justified scientifically as programs advance.² Comparability is positioned less as a compliance checklist and more as a life cycle tool grounded in risk assessment and process understanding. This logic aligns with European Medicines Agency (EMA) guidance on managing comparability across sites and process changes for advanced therapy medicinal products.³ Ginty underscores that the distinction between minor and major changes cannot be defined abstractly: “It’s entirely dependent on how the change impacts the critical quality attributes of the product. Without risk assessment and / or data, you can’t call anything minor or major with confidence.”

Hewitt raised a complementary concern from an industry perspective: that codifying flexibility could be misread as permission to bypass comparability altogether. “The danger is that some developers will hear ‘flexibility’ and assume comparability can be skipped rather than managed,” he warned. “That’s where problems surface later—when programs reach inspection or transfer into commercial manufacturing environments.”

The announcement also addresses process validation expectations, acknowledging that traditional paradigms, such as three process performance qualification (PPQ) lots are not always feasible for CGTs. Instead, the FDA ties validation strategies to the level of process understanding and the realities of limited batch numbers, and it recognizes scenarios where concurrent release may be necessary. However, much of this guidance already exists in fragmented form across Q&As and existing documents; what’s new is that it’s been pulled together and communicated more clearly.

Across all three areas — clinical-stage manufacturing, comparability, and validation — the agency draws an explicit boundary. The FDA does not waive expectations for safety, purity, or potency. Flexibility does not reduce regulatory responsibility; it increases the burden of scientific justification.

Far from reducing the importance of specialized manufacturing partners, the FDA’s clarification of regulatory flexibility amplifies the strategic role of contract development and manufacturing organizations (CDMOs). CGT manufacturing remains capital-intensive, technically fragile, and heavily dependent on experienced personnel. At the same time, market volatility and shifting investment priorities have created persistent mismatches between clinical pipelines and available manufacturing capacity. In this environment, CDMOs increasingly function not as outsourced labor, but as risk-absorbing infrastructure for the sector.

Regulatory flexibility does not remove complexity; it redistributes it. Drug developers must still demonstrate control over highly variable biological processes, justify changes scientifically, and maintain continuity of product quality across development stages and manufacturing sites. CDMOs are often the entities that operationalize these requirements, translating regulatory language into controlled execution frameworks. As Ginty observes, this mode of working is already familiar to experienced manufacturing partners. “Most CDMOs in this space have been operating under these flexible expectations for years,” he said. “They understand how to apply them without confusing flexibility with a drop in standards.”

This role becomes particularly important at the interface between early development and commercialization. Smaller or academically rooted programs may interpret the FDA’s message as permission to defer difficult manufacturing decisions. CDMOs, by contrast, must operate under inspection-ready conditions and anticipate late-stage regulatory scrutiny from the outset.

By absorbing technical, regulatory, and operational risk, CDMOs increasingly anchor continuity across phases and sites. They preserve process knowledge through technology transfers, support comparability strategies as manufacturing evolves, and provide the infrastructure needed to implement automation, analytics, and validation under constrained batch numbers. In doing so, they act as stabilizing intermediaries between regulatory flexibility and commercial reality.

Regulatory flexibility does not simplify manufacturing; instead, it shifts the burden toward execution excellence.

The FDA’s emphasis on flexibility grounded in process understanding places manufacturing technology at the center of regulatory strategy. Tools such as automation, closed systems, process analytical technology (PAT), and real-time release testing (RTRT) are not presented as optional upgrades but as practical mechanisms for maintaining control when traditional batch paradigms and large validation data sets are not feasible. At the same time, technology can become a risk point if its role in process control is misunderstood or poorly justified.

Automation and closed-system manufacturing directly address two of the core challenges in CGT production: operator-driven variability and contamination risk. For processes characterized by small batch sizes and patient-limited starting material, even minor procedural deviations can have disproportionate effects on product quality. Automated platforms reduce manual interventions and standardize critical steps, while closed systems support reproducibility and environmental control across runs.

Hewitt argues that automation should be viewed primarily as an operational improvement rather than a fundamental process change. “If a robot is doing exactly what a human operator used to do, the manufacturing process hasn’t changed — the way in which we interact with the process, human versus robotics, has,” he notes. “We swap in different operators all the time without performing a comparability study, so we need to be careful about how we define these transitions.” His point reflects a broader concern that new technologies may be treated as regulatory disruptions rather than as continuity tools if not framed correctly.

Ginty approached the issue from a different angle, emphasizing perception as much as mechanics. He suggested that FDA’s public articulation of flexibility may reduce the fear historically associated with adopting new manufacturing approaches. “Technology innovators may look at the CMC requirements and think, ‘How on earth are we supposed to do all this for phase I?’ Anything that lowers that fear factor and lets people try more controlled, automated approaches is positive, perception is key” he says. In this sense, automation and closed systems serve not only technical functions but also strategic ones, enabling developers to design processes that are defensible across development stages rather than reinvented at each phase.

PAT provides real-time insight into critical process parameters and quality attributes, allowing manufacturers to detect disturbances as they occur rather than after batch completion. This capability is especially important for CGTs, where end-product testing may be constrained by limited material, short shelf lives, or complex potency assays. PAT shifts quality assurance upstream into the process itself, aligning closely with FDA’s emphasis on process understanding and risk-based control strategies.

This alignment is essential to making flexibility credible, as flexibility only works if it’s grounded in data and in an understanding of how changes affect your critical quality attributes. Without that foundation, adaptive oversight becomes speculation rather than science. PAT enables developers and CDMOs to build that foundation incrementally, using in-process measurements to justify decisions about release criteria, comparability, and validation strategies.

Regulators don’t think in terms of cost or convenience — they think in terms of risk. From that perspective, PAT is not a tool for speeding production but for demonstrating control under uncertainty. Real-time monitoring can show that variability is being managed within defined boundaries, even when batch numbers are small or process changes are unavoidable. This shifts the discussion with regulators from whether flexibility is permissible to whether risk has been adequately characterized and mitigated.

RTRT extends the PAT concept by allowing release decisions to be based on in-process data rather than solely on end-product testing, provided the scientific justification is sound. The FDA frames RTRT as a conditional capability rather than a default approach, particularly relevant when lot numbers are constrained and traditional validation paradigms are impractical.²

Hewitt points to the operational implications of this shift, arguing that eliminating unnecessary aseptic process simulations and repeated rehearsal runs could unlock manufacturing capacity for advanced therapies. “We stop real production to practice making product,” he observed. “If we can rely more on in-process control and less on ritualized testing that doesn’t further diminish risk, we gain time and throughput without compromising safety.” In this view, RTRT is less about accelerating approval and more about reallocating effort toward activities that genuinely improve control.

Ginty cautions, however, that RTRT cannot be treated as a shortcut. “You still have to make a science-based argument for why this data is sufficient,” he notes. “Otherwise, you’re just moving uncertainty around.” The same principle applies across automation and PAT: technology enables flexibility only when it strengthens the link between process behavior and product quality.

These technologies illustrate both the promise and the tension embedded in FDA’s announcement. They offer practical means to implement phase-appropriate control, but they also demand a higher level of analytical rigor and regulatory discipline. Flexibility, in this context, is not a retreat from standards but a reconfiguration of how those standards are met, through execution systems that can support scientific justification in the absence of large data sets.

The FDA’s clarification of permissible flexibility places greater emphasis on when and how manufacturing changes are planned, rather than simply whether they occur. For sponsors, this shifts comparability from a late-stage regulatory hurdle into an early design consideration. Manufacturing strategies that anticipate evolution — across scale, site, and technology — are more likely to avoid friction when programs advance into pivotal trials or commercial supply.

Early planning is particularly critical for tech transfer and scale-out decisions. Comparability challenges are amplified when process changes are introduced after clinical data have already been generated, especially if those changes affect critical quality attributes. Both the FDA and the European Medicines Agency (EMA) frame comparability as a life cycle responsibility, including when manufacturing is transferred across sites or partners. This approach assumes continuity of analytical methods, process knowledge, and control strategies rather than reinvention at each transition point.

Ginty emphasizes the regulatory consequences of postponing these discussions. “If you don’t tell regulators about process changes when they happen, you’re creating risk for yourself later,” he notes. “It may not surface until a facility inspection or during BLA review, but that’s when it becomes much harder to explain.” In this context, flexibility increases the importance of sponsor transparency and documentation rather than diminishing it. It’s a two-way street.”

Focusing on the implications for platform-based manufacturing strategies, particularly for viral vectors and other repeatable production systems, Hewitt argues that multi-site and multi-program operations should be framed around shared risk profiles rather than treated as entirely new products each time a gene of interest changes. “If the plasmids, the cell line, and the analytics are the same, that’s a platform,” he said. “The risk doesn’t reset just because the transgene does.” This perspective supports a more rational approach to scale-out and site expansion, where continuity of process and control can be defended scientifically across programs.

In this vein, tech transfer and multi-site strategies should be designed with regulatory continuity in mind from the outset. CDMOs increasingly serve as life cycle anchors in this process — preserving institutional knowledge, managing comparability across transitions, and providing the infrastructure needed to implement consistent control strategies as manufacturing footprints expand.

For developers, the FDA’s flexible view on CMC for CGTs does not reduce the burden of decision-making — it reshapes it. The emphasis shifts from whether flexibility is allowed to whether a program is equipped to use it responsibly. This places greater weight on the capabilities of manufacturing partners and on the depth of process knowledge embedded in development plans.

Rather than treating flexibility as a shortcut, sponsors must evaluate CDMOs on their ability to demonstrate control under uncertainty. That begins with process understanding: how well critical quality attributes are defined, how changes are assessed against them, and how data are generated to support scientific justification.

Technology maturity becomes a second differentiator. Automation, PAT, and integrated analytics are not simply efficiency tools; they are the mechanisms by which flexible regulatory models become defensible. Sponsors need partners who can deploy these tools in a way that supports comparability, validation, and release strategies when batches are limited and traditional paradigms do not apply.

Experience with validation under constrained conditions is equally important. Process performance qualification and concurrent release models demand judgment grounded in prior regulatory interaction and inspection history. Hewitt emphasizes that this reality ultimately defines success: “You can talk about flexibility all you want, but inspection is where theory meets practice. That’s where you find out if your controls really hold up.”

CGT developers that select partners based solely on capacity or speed risk misaligning regulatory intent with operational execution. Those that prioritize process rigor, analytical depth, and inspection-ready systems are better positioned to translate the FDA’s clarified stance into sustainable development strategies. In this environment, flexibility becomes not a reduction in expectations, but a test of whether organizations can manage complexity with discipline.

The FDA’s announcement does not mark a departure from established regulatory principles; it clarifies how flexibility can be applied within them. By making long-standing practices more transparent, the agency has reinforced that scientific justification, process understanding, and risk-based control remain the foundation of CMC oversight for CGTs

What changes is not the standard but the locus of responsibility. Flexibility places greater weight on manufacturing strategy and execution quality: the ability to design processes that can evolve without compromising product integrity. Technologies such as automation, PAT, and real-time release testing offer practical mechanisms to support this model but only when deployed within disciplined control frameworks rather than as shortcuts.

However, the consequences of misreading the message extend beyond individual programs. “Flexibility without discipline doesn’t just hurt one product,” Hewitt notes. “It risks damaging confidence in the entire sector.” In that sense, the announcement is as much a test of industry maturity as it is a regulatory clarification.

1. FDA Increases Flexibility on Requirements for Cell and Gene Therapies to Advance Innovation. U.S. Food and Drug Administration. 11 Jan. 2026.

2. “Flexible Requirements for Cell and Gene Therapies to Advance Innovation.” U.S. Food and Drug Administration. 11 Jan. 2026.

3. “Questions and answers on comparability considerations for advanced therapy medicinal products (ATMP) – Scientific guideline.” European Medicines Agency. 13 Dec. 2019.